Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Furosemide (Furo) effect on urine pH. Urine pH of wild-type (WT; A) and β4-knockout (β4-KO; B) on day −1, 1, 4, 7, and 11 of control (Ctrl) and Furo treatments or on day −1, 1, 4, and 7 of Furo + acetazolamide (Actz) treatment. *P < 0.05 vs. HK + Ctrl water, #P < 0.05 vs. Day –1, analyzed with two-way repeated-measures ANOVA with a post hoc Holm-Sidak test (P < 0.001 for both treatment and days with interaction P < 0.01). n = 12–14 for WT Ctrl and Furo; N = 7 – 8 for β4-KO Ctrl and Furo; N = 4 for WT Furo + Actz; n = 3 for β4-KO Furo + Actz.

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques: Knock-Out

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Blood measurements after 11 days (or 7 days for HK + Furo Actz) of treatment

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques:

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Furosemide (Furo) effect on plasma [K+] and renal K+ clearance in mice on regular diet (RD) and high-K+ diet (HK). A and B: plasma [K+] and renal K+ clearance of WT on RD on day 11 of control (Ctrl) or Furo treatments. *P < 0.05 vs. RD + Ctrl analyzed with Student’s t-test; n = 4 for Ctrl, n = 6 for Furo. C and D: plasma [K+] and renal K+ clearance of WT and β4-knockout (β4-KO) on day 11 of Ctrl and Furo treatment or day 7 of Furo + acetazolamide (Actz) treatment. *P < 0.05 vs. HK + Ctrl; #P < 0.05 vs. HK + Furo, analyzed with two-way ANOVA with a post hoc Tukey test (P < 0.001 for treatment in plasma [K+]; P < 0.01 for treatment in renal K+ clearance); n = 12 – 14 for WT HK + Ctrl and HK + Furo; n = 7 – 8 for β4-KO HK + Ctrl and HK + Furo; n = 4 for WT HK + Furo Actz; n = 3 for β4-KO HK + Furo Actz.

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques: Knock-Out

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Furosemide (Furo) effect on urinary K+ excretion (UKV̇) normalized to kidney weight in mice on high-K diet (HK). UKV̇ of wild-type (WT; A) and β4-knockout (β4-KO; B) on day −1, 1, 4, 7, and 11 of control (Ctrl) and Furo treatment or on day −1, 1, 4, and 7 of Furo + acetazolamide (Actz) treatment. *P < 0.05 vs. HK + Ctrl; #P < 0.05 vs. day −1, analyzed with two-way repeated measures ANOVA (P < 0.05 for drug treatment in WT) with a post hoc Holm-Sidak test; n = 12–14 for WT HK + Ctrl and HK + Furo; n = 7–8 for β4-KO HK + Ctrl and HK + Furo; n = 4 for WT HK + Furo Actz; n = 3 for β4-KO HK + Furo Actz.

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques: Knock-Out

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Metabolic cage measurements after 11 days (or 7 days for HK + Furo Actz) of treatment

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques:

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Correlation between renal K+ clearance and urine pH in wild-type (WT; A) and β4-knockout (β4-KO; B) on high-K+ diet (HK). ●, HK + control (Ctrl) group; ○, HK + furosemide (Furo) group; ▲, HK + Furo acetazolamide (Actz) group; △, HKCl group.

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques: Knock-Out

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Furosemide (Furo) effect on large conductance Ca2+-activated K+ (BK)-β4 expression in the kidney. A: BK-β4 expression in the kidney medulla of wild-type (WT) on high-K diet (HK) treated with control (Ctrl) or Furo water; n = 4/group. B: BK-β4 expression in the kidney cortex of WT on HK treated with Ctrl vs. Furo water. *P < 0.05 vs. HK + Ctrl analyzed with Student’s t-test; n = 7/group. C: BK-β4 expression in the kidney cortex of WT on HK treated with Ctrl vs. Furo acetazolamide (Actz) water; n = 4/group.

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques: Expressing

Journal: American Journal of Physiology - Renal Physiology

Article Title: Furosemide reduces BK-αβ4-mediated K + secretion in mice on an alkaline high-K + diet

doi: 10.1152/ajprenal.00223.2018

Figure Lengend Snippet: Furosemide concentrations in urine and plasma of WT and BK-β4-KO

Article Snippet: Primary antibodies included anti-BK-β4 (rabbit polyclonal, diluted 1:500; Alomone Laboratories, Jerusalem, Israel), anti-NHE3 (mouse monoclonal, diluted 1:200; Invitrogen, Carlsbad, CA), and anti-V-ATPase B1 (rabbit polyclonal, diluted 1:200; GeneTex, Irvine, CA).

Techniques:

Journal: Acta Pharmaceutica Sinica. B

Article Title: Deficiency of anti-inflammatory cytokine IL-4 leads to neural hyperexcitability and aggravates cerebral ischemia–reperfusion injury

doi: 10.1016/j.apsb.2020.05.002

Figure Lengend Snippet: Upregulation of Nav1.1 and downregulations of KCa3.1 and α 6 subunit of GABA A receptors in the cortex from Il-4 −/− mice and supplemental IL-4 increases KCa3.1 and α 6 mRNA expressions. Upregulation of Nav1.1 mRNA expression and downregulations of KCa3.1 and α 6 subunit of GABA A receptors mRNA expression, in cortical tissues (A) and cortical neurons (B) from Il-4 −/− mice. (C) Nav1.1 protein expression in primary mouse cortical neurons by immunostaining and upregulation of Nav1.1 protein in Il-4 −/− mice ( n = 6 mice). (D) The image staining with KCa3.1 antibody (green), NeuN antibody (red, a neuronal-specific nucleus marker) and DAPI (blue, a nucleus marker). Downregulation of KCa3.1 protein in Il-4 −/− mice ( n = 4 mice, Mann Whitney test). (E) Downregulation of α 6 subunit of GABA A protein in Il-4 −/− mice ( n = 4 mice). Increased mRNA expressions of KCa3.1 and α 6 subunit in Il-4 −/− (F) and Il-4 +/+ (G) cortical neurons after supplementing IL-4 (20 ng/mL) in culture for 7 days. Data are expressed as the mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01 and ∗∗∗ P < 0.001 compared with their controls. The numbers at the bottom of the bars indicate the number of repeats or mice in the group.

Article Snippet: After blocking by 5% milk, PVDF membranes were incubated with primary antibodies at 4 °C overnight such as rat anti-IL-4 antibody (1:500, Abcam, ab11524), mouse monoclonal anti-KCa3.1 antibody (1:250, Alomone, ALM-051), rabbit anti-Nav1.1 antibody (1:250, Alomone, ASC-001), rabbit GABA A R α 6 Polyclonal Antibody (1:200, Alomone, AGA-004), mouse anti- β -actin antibody (1:5000, Abcam) and mouse anti-GAPDH antibody (1:5000, Abcam).

Techniques: Expressing, Immunostaining, Staining, Marker, MANN-WHITNEY

Journal: Acta Pharmaceutica Sinica. B

Article Title: Deficiency of anti-inflammatory cytokine IL-4 leads to neural hyperexcitability and aggravates cerebral ischemia–reperfusion injury

doi: 10.1016/j.apsb.2020.05.002

Figure Lengend Snippet: A proposed molecular mechanism underlying increased neural excitabilities and susceptibility to ischemic injury caused by IL-4 deficiency. IL-4 binding to IL-4R actives IL-4 pathway. IL-4 deficiency alters gene transcriptions by downregulating the Kcnn4 gene encoding KCa3.1 protein and Gabra6 gene encoding GABA A receptor chloride channel and upregulating the Scna1 gene encoding Nav1.1 protein through IL-4 signaling pathways. Downregulation of KCa3.1 channels and tonic GABA A receptors can reduce potassium outflow and chloride inflow in neurons, leading to enhanced neuronal firings through membrane depolarization. The upregulation of Nav1.1 channels can increase sodium inflow in neurons. All these alterations can enhance neuronal hyperexcitability and glutamate release from excitatory axon terminals, ultimately increasing susceptibility to ischemic injury. Conversely, enhancement of IL-4 signaling through supplemental IL-4 can increase KCa3.1 and α 6 subunit of GABA A receptors in cortical neurons and reverse neuronal hyperexcitability, thus exerting neuroprotection against ischemic injury.

Article Snippet: After blocking by 5% milk, PVDF membranes were incubated with primary antibodies at 4 °C overnight such as rat anti-IL-4 antibody (1:500, Abcam, ab11524), mouse monoclonal anti-KCa3.1 antibody (1:250, Alomone, ALM-051), rabbit anti-Nav1.1 antibody (1:250, Alomone, ASC-001), rabbit GABA A R α 6 Polyclonal Antibody (1:200, Alomone, AGA-004), mouse anti- β -actin antibody (1:5000, Abcam) and mouse anti-GAPDH antibody (1:5000, Abcam).

Techniques: Binding Assay

Journal: Cell calcium

Article Title: Differential modulation of SK channel subtypes by phosphorylation.

doi: 10.1016/j.ceca.2020.102346

Figure Lengend Snippet: Fig. 1. The apparent Ca2+ sensitivity of SK1 and IK channel subtypes is more decreased than that of the SK3 and SK2 subtypes in immortal ized endothelial cells. Concentration-dependent activation by Ca2+ of the SK channel subtypes heterologously expressed in HEK293 cells (A) and immortalized endothelial cells (B). (C) EC50 values for the activation by Ca2+, recorded from SK channel subtypes expressed in HEK293 cells (HEK) and immortalized endothelial cells (ET). All data are shown as mean ± S.E.M (n = 6-11, **P < 0.01, ***P < 0.001, Two-way ANOVA followed by Tukey’s post hoc tests).

Article Snippet: The proteins were transferred to PVDF membranes and incubated overnight at 4 °C with primary GFP antibody (1:2000; Invitrogen, Lot: 2,015,993), SK1 antibody (1:1000; RayBiotech, Lot: 907,002,018), SK2 antibody (1:200; Alomone Labs, Lot: APC028AN2325), SK3 antibody (1:200; Alomone Labs, Lot: APC025AN1125), IK antibody (1:1000; Santa Cruz, Lot: I2319), mitochondria marker Cytochrome C antibody (1:1000; Novus Biologicals, Lot: AB0115109A-2), ER marker GRP78/HSPA5 (1:4000; Novus Biologicals, Lot: H-1) antibody or plasma membrane marker sodium potassium ATPase alpha 1 (1:4000; Novus Biologicals, Lot: B-5) antibody.

Techniques: Concentration Assay, Activation Assay

Journal: bioRxiv

Article Title: Hippocampal cell- and circuit-specific differences in mitochondrial form and function

doi: 10.64898/2025.12.16.694759

Figure Lengend Snippet: A.Representative coronal image of the hippocampus showing CA2 neurons (labeled with RGS14) and sparse, cre-dependent labeling of mitochondria (Mito-GFP) B.Representative high magnification images of Mito-GFP and RFP-labeled secondary dendrites in CA1 SR (i) and SLM (ii). C.Representative high magnification images of Mito-GFP and RFP-labeled secondary dendrites in CA2 SR (i) and SLM (ii). MitoTag-GFP images are scaled to the same fluorescence range. RFP images are scaled to visualization. D.Histogram showing the percent cumulative frequency of non-normalized mitochondria areas in CA1 and CA2 SR and SLM. CA1 SR n = 1866 mitochondria from 111 dendrites, SLM n = 2387 mitochondria from 122 dendrites; CA2 SR n = 1653 mitochondria from 96 dendrites, CA2 SLM n = 2159 mitochondria from 119 dendrites from 8 mice. E.Bar plot of average mitochondrial areas per animal (N= 8 mice). Data are normalized to each animal average. (paired two-way ANOVA, main effect of subregion F(1, 7) = 33.32, p=0.0007 and main effect of layer F(1, 7) = 86.18, p<0.0001, Fisher’s LSD posthoc tests are shown on the plot) F.Bar plot of average dendrite areas per animal (N= 8 mice). Data are normalized to each animal average. (paired two-way ANOVA, no effect of subregion F (1, 7) = 4.069, p=0.0835, no effect of layer F(1, 7) = 0.9857 p=0.3539) G.Bar plot of percent area of the dendrite occupied by mitochondria. (paired two-way ANOVA, main effect of subregion F(1, 7) = 16.11, p=0.0051, and layer F(1, 7) = 39.96, p=0.0004, Fisher’s LSD posthoc tests are shown on the plot)*p <0.05; **p<0.01; ***p<0.001. Scale bars = 100 µm (A), 2 µm (C). Error bars are average ± SEM.

Article Snippet: Sections were immunostained with mouse-anti-RGS14 (1:500, NeuroMab cat# 75-170, RRID: AB_2877352) as a CA2 marker as well as rabbit-anti-OPA1 (1:200, Proteintech cat# 27733-1-AP, RRID: AB_2810292) or rabbit-anti-MFF (1:500, Proteintech cat# 17090-1-AP, RRID: AB_2142463).

Techniques: Labeling, Fluorescence

Journal: bioRxiv

Article Title: Hippocampal cell- and circuit-specific differences in mitochondrial form and function

doi: 10.64898/2025.12.16.694759

Figure Lengend Snippet: A.Representative coronal tile image of OPA1 and CA2 marker RGS14 in the hippocampus. Arrowheads denote CA2 cell body borders. B.The same image as in A with only OPA1. C.Bar plot of OPA1 fluorescence intensity in CA1 and CA2 SP, SR and SLM normalized to the animal average. (Paired two-way ANOVA, main effect of subregion (F(1,7) =6.623, p=0.0368), layer (F(2,14)=52.02, p<0.0001), and interaction effect of subregion x layer (F(2,14) =86.69, p<0.0001, N = 8 mice, Tukey’s posthoc tests are shown on the plot). D.Representative coronal tile image of MFF and CA2 marker RGS14 in the hippocampus. Arrowheads denote CA2 cell body borders. E.The same image as in D with only MFF. F.Quantification of MFF fluorescence intensity in CA1 and CA2 SP, SR and SLM normalized to the animal average. (Paired two-way ANOVA, main effect of subregion (F(2, 14) = 306.9, p<0.0001) with an interaction effect of subregion x layer (F(2, 14) = 32.21, p<0.0001, N = 8 mice, Tukey’s posthoc tests are shown on the plot). ***p<0.001 ; ****p<0.0001. Scale bar = 100 µm. Error bars are average ± SEM.

Article Snippet: Sections were immunostained with mouse-anti-RGS14 (1:500, NeuroMab cat# 75-170, RRID: AB_2877352) as a CA2 marker as well as rabbit-anti-OPA1 (1:200, Proteintech cat# 27733-1-AP, RRID: AB_2810292) or rabbit-anti-MFF (1:500, Proteintech cat# 17090-1-AP, RRID: AB_2142463).

Techniques: Marker, Fluorescence

Journal: bioRxiv

Article Title: Hippocampal cell- and circuit-specific differences in mitochondrial form and function

doi: 10.64898/2025.12.16.694759

Figure Lengend Snippet: A.Representative coronal live slice images of CA1 mitochondrial calcium pre (i) and post KCl treatment (ii). B.Normalized average mito-RGECO intensity line plots in CA1 layers relative to distance from stratum oriens (SO, 0.0). The thin lines represent the average trace per mouse normalized by the average intensity within each slice. Multiple slices from the same mouse were averaged to produce a single line per mouse. The thicker line is the average of all animals. (N=6 mice, 11 slices). C.Representative horizontal live slice images of CA2 mitochondrial calcium at baseline (i) and post KCl treatment (ii). D.Normalized average mito-RGECO intensity line plots in CA2 layers as in B. (N=9 mice, 12 slices). E.Quantification of KCl-induced change in mitochondrial calcium fluorescence normalized to baseline (ΔF/F) plotted as an average per animal (N=6-9 mice, 1-3 slices per mouse, 11 CA1 slices, 12 CA2 slices). No significant differences in subregion, layer, or interactions (two-way ANOVA). F.The ratio of mitochondrial calcium signals in SLM to SR at baseline and post KCl treatment (two-way ANOVA, main effect of subregion, F (1,13) = 8.244, p=0.0136, Fisher’s LSD posthoc tests are shown on the plot). G.Representative coronal live slice images of CA1 GCAMP6f cytosolic calcium levels pre (i) and post KCl (ii). The same slice is shown as in A. H.Normalized average GCaMP6f intensity line plots in CA1 layers as in B. I.Representative horizontal live slice images of CA2 GCAMP6f cytosolic calcium levels pre (i) and post KCl (ii). The same slice is shown as in C. J.Normalized average GCAMP6f intensity line plots in CA2 layers as in B. Note the lack of a peak in SLM relative to SR as seen in D. *p<0.05 p**<0.01. Scale = 100 µm. Error bars are average ± SEM. The brightness of images in A, C, G & I are optimized per slice.

Article Snippet: Sections were immunostained with mouse-anti-RGS14 (1:500, NeuroMab cat# 75-170, RRID: AB_2877352) as a CA2 marker as well as rabbit-anti-OPA1 (1:200, Proteintech cat# 27733-1-AP, RRID: AB_2810292) or rabbit-anti-MFF (1:500, Proteintech cat# 17090-1-AP, RRID: AB_2142463).

Techniques: Fluorescence

Journal: bioRxiv

Article Title: Hippocampal cell- and circuit-specific differences in mitochondrial form and function

doi: 10.64898/2025.12.16.694759

Figure Lengend Snippet: A.Representative tile image of mito-RGECO (i) and CA2 marker RGS14 (ii) in a perfusion fixed, coronal section of the hippocampus (dashed line denotes the border of SR and SLM). B.Representative high magnification image of RGS14 labeled CA2 neurons (cyan) expressing mito-RGECO (magenta) and sparse, cre-dependent labeling of MitoTag-GFP (green). Insets of a CA2 cell soma and proximal dendrites. Note the mito-RGECO signal is localized to the mitochondrial matrix surrounded by the GFP-labeled outer membrane. C.Representative images of mito-RGECO in CA1 (i) and CA2 (ii). Insets show mito-RGECO in distal dendrites. D.Normalized average mito-RGECO intensity line plots across CA1 and CA2 layers relative to distance from stratum oriens (SO). Data points are normalized by the average intensity within a subregion per animal. Thus, CA1 and CA2 data should not be directly compared, but rather the layer differences within each subregion. The data shown are animal averages ± SEM. (CA1 N=5 mice, CA2 N=7 mice). E.Average ratio of SR to SLM mito-RGECO fluorescence intensities. (unpaired two tailed t-test, CA1 N=5 mice, CA2 N=7 mice) ***p<0.0001. Scale bars = 100 µm (A, C), 20 µm (B), 5 µm (B, C insets). Error bars are average ± SEM.

Article Snippet: Sections were immunostained with mouse-anti-RGS14 (1:500, NeuroMab cat# 75-170, RRID: AB_2877352) as a CA2 marker as well as rabbit-anti-OPA1 (1:200, Proteintech cat# 27733-1-AP, RRID: AB_2810292) or rabbit-anti-MFF (1:500, Proteintech cat# 17090-1-AP, RRID: AB_2142463).

Techniques: Marker, Labeling, Expressing, Membrane, Fluorescence, Two Tailed Test

Journal: bioRxiv

Article Title: Hippocampal cell- and circuit-specific differences in mitochondrial form and function

doi: 10.64898/2025.12.16.694759

Figure Lengend Snippet: A.Post-fixed CA1 coronal slice stained for GFP (GCaMP6f, i), RFP (mito-RGECO, ii), and CA1 marker CALB1 (iii). Zoomed inset of SP (iv) to show mito-RGECO expression in CALB1 expressing CA1 neurons. B.Post-fixed CA2 horizontal slice stained for GFP (GCaMP6f, i), RFP (mito-RGECO, ii), and CA2 marker NECAB2 (iii). Zoomed inset of SP (iv) to show mito-RGECO expression in NECAB2 expressing CA2 neurons. C.Representative tile image of sparse hSyn1-cre driven tdtomato labeling of CA1 and CA2 neurons in a coronal section. CA2 neurons are labeled with PCP4. D.Higher magnification of CA1 to show dendritic banding in SLM. Nuclei are labeled with DAPI. E.Higher magnification of CA2 to show dendrites are out of plane. Nuclei are labeled with DAPI. Scale bars = (Ai) 100 µm, (Aiv) 50 µm, (C) 100 µm, (D) 100 µm

Article Snippet: Sections were immunostained with mouse-anti-RGS14 (1:500, NeuroMab cat# 75-170, RRID: AB_2877352) as a CA2 marker as well as rabbit-anti-OPA1 (1:200, Proteintech cat# 27733-1-AP, RRID: AB_2810292) or rabbit-anti-MFF (1:500, Proteintech cat# 17090-1-AP, RRID: AB_2142463).

Techniques: Staining, Marker, Expressing, Labeling